Literature DB >> 16896588

Estimation of cancer risks from radiotherapy of benign diseases.

Klaus-Rüdiger Trott1, Friedrich Kamprad.   

Abstract

BACKGROUND: The effective-dose method which was proposed by the ICRP (International Commission of Radiation Protection) for the estimation of risk to the general population from occupational or environmental, low-dose radiation exposure is not adequate for estimating the risk of cancer induction by radiotherapy of malignant or nonmalignant diseases.
METHODS: The risk of cancer induction by radiotherapy of benign diseases should be based on epidemiologic data directly derived from follow-up studies of patients who had been given radiotherapy for nonmalignant diseases in the past.
RESULTS: Risk factors were derived from epidemiologic studies of patients treated with irradiation for nonmalignant diseases to be used for selecting treatment options and optimizing treatment procedures.
CONCLUSION: In most cases, cancer risks estimated by the effective-dose method may overestimate the true risks by one order of magnitude, yet in other cases even may underestimate it. The proposed method using organ-specific risk factors may be more suitable for treatment planning.

Entities:  

Mesh:

Year:  2006        PMID: 16896588     DOI: 10.1007/s00066-006-1542-8

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  38 in total

Review 1.  [Radiotherapeutic management of lymphatic fistulas : An effective but disregarded therapy option].

Authors:  D Habermehl; G Habl; H-H Eckstein; F Meisner; S E Combs
Journal:  Chirurg       Date:  2017-04       Impact factor: 0.955

2.  Second malignancies in high‑dose areas of previous tumor radiotherapy.

Authors:  Birgitta Welte; Peter Suhr; Dirk Bottke; Detlef Bartkowiak; Wolfgang Dörr; Klaus Rüdiger Trott; Thomas Wiegel
Journal:  Strahlenther Onkol       Date:  2010-02-22       Impact factor: 3.621

3.  Prospective study of exclusive strontium-/yttrium-90 beta-irradiation of primary and recurrent pterygia with no prior surgical excision. Clinical outcome of long-term follow-up.

Authors:  Iraklis Vastardis; Bojan Pajic; Richard H Greiner; Brigitte Pajic-Eggspuehler; Daniel M Aebersold
Journal:  Strahlenther Onkol       Date:  2009-12       Impact factor: 3.621

Review 4.  Paraspinal extramedullary hematopoiesis in patients with thalassemia intermedia.

Authors:  Rachid Haidar; Hani Mhaidli; Ali T Taher
Journal:  Eur Spine J       Date:  2010-03-05       Impact factor: 3.134

5.  [Radiotherapy of non-malignant diseases. Past, present and future].

Authors:  M H Seegenschmiedt; O Micke
Journal:  Strahlenther Onkol       Date:  2012-11       Impact factor: 3.621

6.  The Erlangen Dose Optimization Trial for radiotherapy of benign painful shoulder syndrome. Long-term results.

Authors:  O J Ott; S Hertel; U S Gaipl; B Frey; M Schmidt; R Fietkau
Journal:  Strahlenther Onkol       Date:  2014-02-07       Impact factor: 3.621

Review 7.  Radiotherapy for benign disease; assessing the risk of radiation-induced cancer following exposure to intermediate dose radiation.

Authors:  Stephanie R McKeown; Paul Hatfield; Robin J D Prestwich; Richard E Shaffer; Roger E Taylor
Journal:  Br J Radiol       Date:  2015-10-14       Impact factor: 3.039

8.  Radiotherapy for calcaneodynia. Results of a single center prospective randomized dose optimization trial.

Authors:  O J Ott; C Jeremias; U S Gaipl; B Frey; M Schmidt; R Fietkau
Journal:  Strahlenther Onkol       Date:  2013-02-28       Impact factor: 3.621

9.  Radiotherapy for achillodynia : results of a single-center prospective randomized dose-optimization trial.

Authors:  O J Ott; C Jeremias; U S Gaipl; B Frey; M Schmidt; R Fietkau
Journal:  Strahlenther Onkol       Date:  2012-12-21       Impact factor: 3.621

10.  The Erlangen Dose Optimization trial for low-dose radiotherapy of benign painful elbow syndrome. Long-term results.

Authors:  O J Ott; S Hertel; U S Gaipl; B Frey; M Schmidt; R Fietkau
Journal:  Strahlenther Onkol       Date:  2014-01-16       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.